Long-Term, Drug-Free Remission of Sympathetic Ophthalmia with High-Dose, Short-Term Chlorambucil Therapy – Corrected Proof
Objective: To evaluate the safety and effectiveness of short-term, high-dose chlorambucil therapy in achieving long-term, drug-free remission in the treatment of sympathetic ophthalmia (SO).Design: Retrospective case series.Participants: Sixteen patients with SO treated with high-dose, short-term chlorambucil therapy between 1970 and 2010.Methods: Descriptive and bivariate analyses were used to characterize disease and outcomes.Main Outcome Measures: Months of disease-free remission, prevalence rate of relapse, and prevalence of serious treatment-related adverse events.Results: Sixteen patients with SO treated with short-term, high-dose chlorambucil were identified. Patients were treated with chlorambucil for a median of 14.0 weeks (mean, 14.5 weeks; range, 12.0–19.0 weeks). Median follow-up was 98.5 (Read more...)